|
|
Post by Clement on Dec 13, 2018 9:55:22 GMT -5
from the earnings call:
"David has done a tremendous amount of work not only on the thought leaders, but the scientific publications, which -- one of the problems that we see is when you go to talk about guidelines and changing guidelines, when you don't have any data published, we're sitting on 65 trials and thousands of patients, they need that data published in order to look at adjusting guidelines or highlighting unique aspects of our product, and so that's a major effort of ours. And you've seen probably this year 10 -- you'll see 10 new publications by the end of the year or early next year come out."
|
|
|
|
Post by mannmade on Dec 13, 2018 11:26:56 GMT -5
Anyone know how many since this statement was made?
|
|
|
|
Post by goyocafe on Dec 13, 2018 12:47:17 GMT -5
Anyone know how many since this statement was made? 1 as far as I know. They’ve referenced the stat publication on a number of occasions. |
|
|
|
Post by mnkdfann on Dec 13, 2018 13:08:44 GMT -5
from the earnings call: "David has done a tremendous amount of work not only on the thought leaders, but the scientific publications, which -- one of the problems that we see is when you go to talk about guidelines and changing guidelines, when you don't have any data published, we're sitting on 65 trials and thousands of patients, they need that data published in order to look at adjusting guidelines or highlighting unique aspects of our product, and so that's a major effort of ours. And you've seen probably this year 10 -- you'll see 10 new publications by the end of the year or early next year come out."AFAIK, no one else has previously remarked upon this but coincidentally Mannkind's booth at the ADA is right by that of Mary Ann Liebert, Inc. Publishers. Mannkind published (at least one) of its papers in one of Mary Ann's journals earlier this year. Unfortunately it is not the most prestigious of publishing houses (I mean its journals are not on the level of the Lancet or JAMA etc.), but I guess it is a perfectly okay middle of the road publisher, and anything helps. I doubt the above is anything more than coincidence. But it is what it is. Maybe Mary Ann's booth will have copies of that Mannkind paper I mentioned to hand out. Or Mannkind's booth highlights its paper in ML's journal at its own booth, and earns good karma from ML towards its future submissions. Feel the synergies! |
|
|
|
Post by mnkdfann on Dec 13, 2018 13:37:17 GMT -5
from the earnings call: "David has done a tremendous amount of work not only on the thought leaders, but the scientific publications, which -- one of the problems that we see is when you go to talk about guidelines and changing guidelines, when you don't have any data published, we're sitting on 65 trials and thousands of patients, they need that data published in order to look at adjusting guidelines or highlighting unique aspects of our product, and so that's a major effort of ours. And you've seen probably this year 10 -- you'll see 10 new publications by the end of the year or early next year come out."On its website, Mannkind includes various poster presentations as publications. So it may be that he was including presentations in his 10 count? Either way, more pubs should be expected soon. www.mannkindcorp.com/research-development/publications/ |
|
|
|
Post by #NoMoreNeedles on Jan 3, 2019 12:55:47 GMT -5
Dr Kendall should publish more in peer reviewed journal with high impact factor ... and buy a few more shares along the way as well.
|
|
|
|
Post by pantaloons on Jan 3, 2019 16:20:12 GMT -5
I apologize in advance if this is a little off-topic and if the following post would be more appropriate in a different (or its own) thread:
Several weeks ago, I read through the UpToDate article regarding inhalable insulin, a considerable portion of which discusses Afrezza (article: "Inhaled insulin therapy in diabetes mellitus"). For those of you unfamiliar with UpToDate, it is a highly utilized and trustworthy resource that practically all healthcare practitioners use for generally unbiased/objective information regarding all medical topics. It is written at the level for healthcare providers to understand and is supported by references to peer-reviewed clinical studies.
I was, unfortunately, overall rather discouraged to read what was written in regard to Afrezza. I will not go into detail here, but it is not portrayed to be nearly as beneficial as rapid-acting insulin analogs. It would not surprise me if many physicians who go to learn about Afrezza are steered away from it, namely due to the information presented on UpToDate. In short, the overall recommendations are in line with recent ADA recommendations.
I do not believe this necessarily means that Afrezza does not have the potential to be proven superior to every other mealtime insulin. Instead, it is likely that the time frame for widespread adoption will take a bit longer than originally anticipated - in other words, it would not be imprudent to keep balanced short-term expectations in mind.
Initial clinical studies are very promising, but larger scale, multi-center studies are not unreasonable to expect before massive adoption. Other drugs that come to mind that have had to prove itself over time include various drugs for hypertension and cardiovascular disease.
I'd like to ask if any other individuals on this board have had a chance to read through this article (it is only available to those with a subscription, most commonly through a hospital or other academic institution.) I would copy & paste key sections of the article here but believe it may violate copyright policies. I have a particular interest in the opinions of those with experience in the healthcare field, especially those who management patients. I appreciate any thoughts/insights you may have on the matter.
|
|
|
|
Post by stevil on Jan 3, 2019 23:03:20 GMT -5
By far the most oft used website/app used by the doctors I rotate with is UpToDate. Next is AAFP because their articles are succinct and easy to read, then DynaMed, although there are a lot of other good ones.
What’s so great about UpToDate is inherent in its name- it spends a considerable amount of resources making sure it has the most current information as more “trustworthy” articles get published. It’ll still make mention of the lesser-powered studies for consideration, but it does all the grunt work for doctors by collating all of the best studies in one place to provide the most current and complete information to make educated recommendations. There is no lack of information to learn in medicine and as much as some posters on here want to criticize doctors for not staying current, they need to direct their anger at the ones responsible for not putting convincing information in the locations doctors actually look to become informed. You can’t learn about what isn’t there.
The previous post gets to the heart of why I’m maybe too aggressive with some posters on here when they say anything other than strong studies and insurance is the reason for lackluster script growth. It has nothing to do with FUD or laziness by physicians. There simply isn’t any good data for doctors to consider once they hear about Afrezza.
The process goes like this:
1. Patient asks doctor if they’ve heard about a certain medication
2. Doctor says no, but I’ll do some research on it and get back to you
3. Doctor goes to UpToDate and sees nothing worthwhile about it.
Few doctors will allow their patients to prescribe carte blanche for themselves. I certainly haven’t come across any, unless it was a one time fill for the patient either for addiction or to get them through until an appointment with the specialist managing their care. But they definitely wouldn’t prescribe a new medication they weren’t familiar about without doing some research. If they do, they likely won’t have their license very long. My point is, even if a patient thinks Afrezza is the greatest thing in the world, it’s not a guarantee that they’ll be handed a prescription for it. Between all the wives tales and Web MDs out there, doctors usually don’t believe a word their patients tell them, especially if the patient is aggressive and makes demands. If there is strong rapport and a healthy relationship, I think you’d see a lot more scripts get written, but even then, what would most likely happen is strong pushback because the relationship is healthy enough for the doc to try to convince their patient to do what they think is in their best interest by avoiding Afrezza.
I presented about Afrezza in front of residents and attendings on my rotation last month and was stuck explaining the science and why it “should” work because I didn’t have enough data to prove that it “did”. It was quite eye-opening to say the least. I’ve become so familiar with Afrezza that I haven’t been doing any further research on it to see what information is actually out there. It was disappointing to say the least...
|
|
|
|
Post by joeypotsandpans on Jan 4, 2019 0:52:28 GMT -5
By far the most oft used website/app used by the doctors I rotate with is UpToDate. Next is AAFP because their articles are succinct and easy to read, then DynaMed, although there are a lot of other good ones. What’s so great about UpToDate is inherent in its name- it spends a considerable amount of resources making sure it has the most current information as more “trustworthy” articles get published. It’ll still make mention of the lesser-powered studies for consideration, but it does all the grunt work for doctors by collating all of the best studies in one place to provide the most current and complete information to make educated recommendations. There is no lack of information to learn in medicine and as much as some posters on here want to criticize doctors for not staying current, they need to direct their anger at the ones responsible for not putting convincing information in the locations doctors actually look to become informed. You can’t learn about what isn’t there. The previous post gets to the heart of why I’m maybe too aggressive with some posters on here when they say anything other than strong studies and insurance is the reason for lackluster script growth. It has nothing to do with FUD or laziness by physicians. There simply isn’t any good data for doctors to consider once they hear about Afrezza. The process goes like this: 1. Patient asks doctor if they’ve heard about a certain medication 2. Doctor says no, but I’ll do some research on it and get back to you 3. Doctor goes to UpToDate and sees nothing worthwhile about it. Few doctors will allow their patients to prescribe carte blanche for themselves. I certainly haven’t come across any, unless it was a one time fill for the patient either for addiction or to get them through until an appointment with the specialist managing their care. But they definitely wouldn’t prescribe a new medication they weren’t familiar about without doing some research. If they do, they likely won’t have their license very long. My point is, even if a patient thinks Afrezza is the greatest thing in the world, it’s not a guarantee that they’ll be handed a prescription for it. Between all the wives tales and Web MDs out there, doctors usually don’t believe a word their patients tell them, especially if the patient is aggressive and makes demands. If there is strong rapport and a healthy relationship, I think you’d see a lot more scripts get written, but even then, what would most likely happen is strong pushback because the relationship is healthy enough for the doc to try to convince their patient to do what they think is in their best interest by avoiding Afrezza. I presented about Afrezza in front of residents and attendings on my rotation last month and was stuck explaining the science and why it “should” work because I didn’t have enough data to prove that it “did”. It was quite eye-opening to say the least. I’ve become so familiar with Afrezza that I haven’t been doing any further research on it to see what information is actually out there. It was disappointing to say the least... I had my endo appointment today, this endo has been prescribing Afrezza since the beginning from the first SNY rep. When I asked him about it the first visit, his words not mine "it's a game changer". What do you suppose differentiates him from most others? At my visit today before the doc came in I was visited by a student on his current rotation, he recognized me from when he was doing his rotation back in April and said hey aren't you the "Afrezza guy" (he distinctly remembered our conversation back in April and it obviously stuck with him), he won't need to see any publication as he is seeing live patients first hand that are having the incredible results and are consistently compliant. I think that will carry quite a bit of weight when he is entering practice if he is going clinical and internal med/family/endo. This particular practice has the Afrezza posters in all the patient rooms as well as the entry area where they do the routine weigh in, bp, and sticks for onsite Hba1c checks. I actually sent a pic to Sports from the room I was in today. At the end of the visit, doc told me how happy he was with my graph readings from the Libre download and my numbers, said "I'll see you in 3 mos. and enjoy Thailand" (heading back to Phuket this coming Tues. armed with Afrezza and my sensors  Hang in there Stevil, my oldest is in 2nd H of his HEME-ONC fellowship, know how tough the hours and lack of sleep can be |
|
|
|
Post by sportsrancho on Jan 4, 2019 7:12:39 GMT -5
|
|
|
|
Post by barnstormer on Jan 4, 2019 7:25:56 GMT -5
Dr Kendall should publish more in peer reviewed journal with high impact factor ... and buy a few more shares along the way as well. He touted at the last ASM about all of the studies and data that MNKD has, hasn't delivered on his promise to get it out into the field yet. BTW he hasn't bought any shares yet as far as I can see. So far he hasn't lived up to the hype. |
|
|
|
Post by #NoMoreNeedles on Jan 17, 2019 10:40:45 GMT -5
I am not able to find any new publications. Anyone else having more luck?
|
|
Hang in there Stevil, my oldest is in 2nd H of his HEME-ONC fellowship, know how tough the hours and lack of sleep can be 
